Setting new standards in information exchange for the pharmaceutical and biotech industry
PODD Speaker Dr. Tugrul Karali from PharmaCircle on whether Injectables are the new Oral
April 25, 2016
Published in the April issue of Contract Pharma, Dr. Karali’s article, “Injectables – The New Oral?,” takes inspiration from his presentation at the PODD (Partnership Opportunities in Drug Delivery) October 2015 Conference. Supported by PharmaCircle data, the article suggests that injectables have become a delivery route of significant interest for Pharma and Specialty Pharma companies.
“Injectables – The New Oral?”
It probably won’t come as a surprise to many that the pharmaceutical industry has been increasingly embracing injectables as a consistently profitable business sector. It may be a surprise though, to find that seven of the top 10 pharmaceuticals by sales in 2014 were injectables.
This is a far cry from a decade earlier where only one product, Amgen’s Epogen, managed to crack the Top 10, sitting in the Number 9 position. Eight of these Top 10 products were oral products, and one, Advair, was an inhalation product. The sharp move towards injectables is the result of a number of important trends that are worth understanding.
About the PODD Conference
This annual Boston-based conference is designed with three purposes:
- To present a strategic level program for pharma and biotech business development professionals with a thorough overview of the latest drug delivery technologies available along with an update on deals and opportunities to improve therapies and extend the life cycle of a drug.
- To provide drug delivery and specialty pharmas with a platform to present their technologies and get the latest insights on what the delivery and formulation needs are.
- To offer ample networking time, facilities and services for one-on-one meetings to establish new business contacts and enhance existing ones.